메뉴 건너뛰기




Volumn 78, Issue 2-3, 2008, Pages 67-71

Prokinetics influence the pharmacokinetics of rabeprazole

Author keywords

Mosapride citrate; Pharmacokinetics; Rabeprazole sodium

Indexed keywords

MOSAPRIDE CITRATE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE;

EID: 54249135372     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000165351     Document Type: Article
Times cited : (23)

References (23)
  • 1
    • 21744438918 scopus 로고    scopus 로고
    • Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status
    • Furuta T, Shirai N, Sugimoto M, Nakamura A, Okudaira K, Kajimura M, Hishida A: Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status. Aliment Pharmacol Ther 2005;22:67-74.
    • (2005) Aliment Pharmacol Ther , vol.22 , pp. 67-74
    • Furuta, T.1    Shirai, N.2    Sugimoto, M.3    Nakamura, A.4    Okudaira, K.5    Kajimura, M.6    Hishida, A.7
  • 2
    • 0021060508 scopus 로고
    • Dose-response study of omeprazole on meal-stimulated gastric acid secretion and gastrin release
    • Londong W, Londong V, Cederberg C, Steffen H: Dose-response study of omeprazole on meal-stimulated gastric acid secretion and gastrin release. Gastroenterology 1983;85:1373-1378.
    • (1983) Gastroenterology , vol.85 , pp. 1373-1378
    • Londong, W.1    Londong, V.2    Cederberg, C.3    Steffen, H.4
  • 3
    • 0031700062 scopus 로고    scopus 로고
    • Nocturnal gastric acidity and breakthrough on different regimens of omeprazole 40 mg daily
    • Hatlebakk JG, Katz PO, Kuo B, Castell DO: Nocturnal gastric acidity and breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998;12:1235-1240.
    • (1998) Aliment Pharmacol Ther , vol.12 , pp. 1235-1240
    • Hatlebakk, J.G.1    Katz, P.O.2    Kuo, B.3    Castell, D.O.4
  • 5
    • 42049114160 scopus 로고    scopus 로고
    • 4 selective agonist, beneficially affects pharmacokinetics of proton pump inhibitor
    • 4 selective agonist, beneficially affects pharmacokinetics of proton pump inhibitor. Gastroenterology 2005;128:A531.
    • (2005) Gastroenterology , vol.128
    • Takeuchi, Y.1    Watanabe, H.2    Imawari, M.3
  • 6
    • 0029977698 scopus 로고    scopus 로고
    • Pharmacokinetics, metabolism and interactions of acid pump inhibitors
    • Anderson T: Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Clin Pharmacokinet 1996;31:9-28.
    • (1996) Clin Pharmacokinet , vol.31 , pp. 9-28
    • Anderson, T.1
  • 9
    • 0035894575 scopus 로고    scopus 로고
    • Serotoninergic neuroenteric modulators
    • Talley NJ: Serotoninergic neuroenteric modulators. Lancet 2001;358:2061-2068.
    • (2001) Lancet , vol.358 , pp. 2061-2068
    • Talley, N.J.1
  • 12
    • 0034819828 scopus 로고    scopus 로고
    • Effect of mosapride citrate on human plasma levels of motilin, gastrin, somatostatin, and secretin
    • Itoh H, Nagago T, Takeyama M: Effect of mosapride citrate on human plasma levels of motilin, gastrin, somatostatin, and secretin. Biol Pharm Bull 2001;24:1072-1075.
    • (2001) Biol Pharm Bull , vol.24 , pp. 1072-1075
    • Itoh, H.1    Nagago, T.2    Takeyama, M.3
  • 13
    • 0032807774 scopus 로고    scopus 로고
    • Review article: Cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole
    • Ishizaki T, Horai Y: Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther 1999;13:27-36.
    • (1999) Aliment Pharmacol Ther , vol.13 , pp. 27-36
    • Ishizaki, T.1    Horai, Y.2
  • 17
    • 1542573393 scopus 로고    scopus 로고
    • Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in Japanese population
    • Fukushima-Uesaka H, Saito Y, Watanabe H, et al: Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in Japanese population. Hum Mutations 2004;23:100.
    • (2004) Hum Mutations , vol.23 , pp. 100
    • Fukushima-Uesaka, H.1    Saito, Y.2    Watanabe, H.3
  • 18
    • 33746446370 scopus 로고    scopus 로고
    • Effect of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes
    • Shimizu M, Uno T, Yasui-Furukori N, Sugawara K, Tateishi T: Effect of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol 2006;62:597-603.
    • (2006) Eur J Clin Pharmacol , vol.62 , pp. 597-603
    • Shimizu, M.1    Uno, T.2    Yasui-Furukori, N.3    Sugawara, K.4    Tateishi, T.5
  • 19
    • 0036432798 scopus 로고    scopus 로고
    • The clinical importance of proton pump inhibitor pharmacokinetics
    • Yacyshyn BR, Thomson ABR: The clinical importance of proton pump inhibitor pharmacokinetics. Digestion 2002;66:67-78.
    • (2002) Digestion , vol.66 , pp. 67-78
    • Yacyshyn, B.R.1    Thomson, A.B.R.2
  • 20
    • 12344321002 scopus 로고    scopus 로고
    • Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: A randomized trial
    • Madan K, Ahuja V, Kashyap PC, Sharma P: Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis Esophagus 2004;17:274-278.
    • (2004) Dis Esophagus , vol.17 , pp. 274-278
    • Madan, K.1    Ahuja, V.2    Kashyap, P.C.3    Sharma, P.4
  • 21
    • 42049120978 scopus 로고    scopus 로고
    • Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy
    • Miyamoto M, Haruma K, Takeuchi K, Kuwabara M: Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy. J Gastroenterol Hepatol 2007;23:746-751.
    • (2007) J Gastroenterol Hepatol , vol.23 , pp. 746-751
    • Miyamoto, M.1    Haruma, K.2    Takeuchi, K.3    Kuwabara, M.4
  • 22
    • 0030801806 scopus 로고    scopus 로고
    • Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: Implications for proarrhythmic potential?
    • Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G: Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Exp Ther 1997;282:220-227.
    • (1997) J Pharmacol Exp Ther , vol.282 , pp. 220-227
    • Carlsson, L.1    Amos, G.J.2    Andersson, B.3    Drews, L.4    Duker, G.5    Wadstedt, G.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.